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 common	  tests,	  such	  as	  t-­‐test	  (please	  specify	  whether	  paired	  vs.	  unpaired),	  simple	  χ2	  tests,	  Wilcoxon	  and	  Mann-­‐Whitney	  
tests,	  can	  be	  unambiguously	  identified	  by	  name	  only,	  but	  more	  complex	  techniques	  should	  be	  described	  in	  the	  methods	  
section;
 are	  tests	  one-­‐sided	  or	  two-­‐sided?
 are	  there	  adjustments	  for	  multiple	  comparisons?
 exact	  statistical	  test	  results,	  e.g.,	  P	  values	  =	  x	  but	  not	  P	  values	  <	  x;
 definition	  of	  ‘center	  values’	  as	  median	  or	  average;
 definition	  of	  error	  bars	  as	  s.d.	  or	  s.e.m.	  
1.a.	  How	  was	  the	  sample	  size	  chosen	  to	  ensure	  adequate	  power	  to	  detect	  a	  pre-­‐specified	  effect	  size?
1.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  sample	  size	  estimate	  even	  if	  no	  statistical	  methods	  were	  used.
2.	  Describe	  inclusion/exclusion	  criteria	  if	  samples	  or	  animals	  were	  excluded	  from	  the	  analysis.	  Were	  the	  criteria	  pre-­‐
established?
3.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  when	  allocating	  animals/samples	  to	  treatment	  (e.g.	  
randomization	  procedure)?	  If	  yes,	  please	  describe.	  
For	  animal	  studies,	  include	  a	  statement	  about	  randomization	  even	  if	  no	  randomization	  was	  used.
4.a.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  during	  group	  allocation	  or/and	  when	  assessing	  results	  
(e.g.	  blinding	  of	  the	  investigator)?	  If	  yes	  please	  describe.
4.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  blinding	  even	  if	  no	  blinding	  was	  done
5.	  For	  every	  figure,	  are	  statistical	  tests	  justified	  as	  appropriate?
Do	  the	  data	  meet	  the	  assumptions	  of	  the	  tests	  (e.g.,	  normal	  distribution)?	  Describe	  any	  methods	  used	  to	  assess	  it.
Is	  there	  an	  estimate	  of	  variation	  within	  each	  group	  of	  data?
Is	  the	  variance	  similar	  between	  the	  groups	  that	  are	  being	  statistically	  compared?
6.	  To	  show	  that	  antibodies	  were	  profiled	  for	  use	  in	  the	  system	  under	  study	  (assay	  and	  species),	  provide	  a	  citation,	  catalog	  
number	  and/or	  clone	  number,	  supplementary	  information	  or	  reference	  to	  an	  antibody	  validation	  profile.	  e.g.,	  





The	  antibodies	  that	  were	  used	  in	  this	  study	  were	  as	  follows:	  mouse	  monoclonal	  antibody	  against	  
EZH2	  (612667,	  BD	  Science);	  rabbit	  polyclonal	  antibody	  against	  SUZ-­‐12	  (20366-­‐1-­‐AP,	  Proteintech,	  
USA);	  mouse	  monoclonal	  antibody	  against	  β-­‐actin	  (ab6276,	  Abcam,	  USA);	  rabbit	  polyclonal	  
antibody	  against	  H3K27Me3	  (07-­‐449,	  Millipore,	  USA);	  rabbit	  polyclonal	  antibody	  against	  H3K9Me3	  
(05-­‐1242,	  Millipore,	  USA);	  rabbit	  polyclonal	  antibody	  against	  H3	  histone	  (AH433,	  Beyotime,	  China);	  
rabbit	  polyclonal	  antibody	  against	  EED	  (16818-­‐1-­‐AP,	  Proteintech);	  rabbit	  polyclonal	  antibody	  
against	  BMI-­‐1	  (10832-­‐1-­‐AP,	  Proteintech);	  rabbit	  polyclonal	  antibody	  against	  PARP	  (AP102,	  
Beyotime,	  China);	  rabbit	  polyclonal	  antibody	  against	  caspase-­‐8	  (13423-­‐1-­‐AP,	  Proteintech,	  USA);	  
rabbit	  polyclonal	  antibody	  against	  caspase-­‐3	  (19677-­‐1-­‐AP,	  Proteintech,	  USA);	  rabbit	  polyclonal	  
antibody	  against	  Bcl-­‐2	  (12789-­‐1-­‐AP,	  Proteintech,	  USA);	  rabbit	  polyclonal	  antibody	  against	  Bax	  
(50599-­‐2-­‐Ig,	  Proteintech,	  USA);	  the	  rabbit	  polyclonal	  antibody	  against	  ubiquitin	  (1646-­‐1,	  Epitomics,	  
USA);	  mouse	  monoclonal	  antibody	  against	  Smurf1	  (sc-­‐100616,	  Santa	  Cruz,	  USA);	  rabbit	  polyclonal	  
antibody	  against	  Smurf2	  (sc-­‐25511,	  Santa	  Cruz,	  USA);	  rabbit	  monoclonal	  antibody	  against	  Bim	  
(2933,	  Cell	  Signal,	  USA);	  and	  mouse	  monoclonal	  antibody	  against	  Flag	  (F1804,	  Sigma,	  USA);	  Methyl-­‐
Histone	  H3	  Antibody	  Sampler	  Kit	  (9847,	  Cell	  Signal,	  USA);	  Tri-­‐Methyl	  Histone	  H3	  Antibody	  Sampler	  
Kit	  (9783,	  Cell	  Signal,	  USA);	  Rabbit	  polyclonal	  antibodies	  against	  H4K20	  methylation	  (ab9051,	  
ab9052,	  ab9053,	  Abcam,	  USA);	  Rabbit	  polyclonal	  antibodies	  against	  EZH1(A5818,	  Abclonal,	  China).	  
YOU	  MUST	  COMPLETE	  ALL	  CELLS	  WITH	  A	  PINK	  BACKGROUND	  
N/A
N/A
No	  animals	  were	  excluded	  from	  the	  analysis
The	  animals	  were	  randomly	  distributed	  to	  each	  group.
After	  5	  days,	  the	  tumor	  sizes	  were	  determined	  using	  micrometer	  calipers,	  and	  the	  nude	  mice	  with	  
similar	  tumor	  volumes	  (eliminating	  mice	  with	  tumors	  that	  were	  too	  large	  or	  too	  small)	  were	  then	  
randomly	  divided	  into	  3	  groups	  (10	  nude	  mice	  per	  group)
No
The	  animal	  studies	  were	  performed	  under	  blinding	  condition.
definitions	  of	  statistical	  methods	  and	  measures:
1.	  Data
the	  data	  were	  obtained	  and	  processed	  according	  to	  the	  field’s	  best	  practice	  and	  are	  presented	  to	  reflect	  the	  results	  of	  the	  
experiments	  in	  an	  accurate	  and	  unbiased	  manner.
figure	  panels	  include	  only	  data	  points,	  measurements	  or	  observations	  that	  can	  be	  compared	  to	  each	  other	  in	  a	  scientifically	  
meaningful	  way.
graphs	  include	  clearly	  labeled	  error	  bars	  for	  independent	  experiments	  and	  sample	  sizes.	  Unless	  justified,	  error	  bars	  should	  
not	  be	  shown	  for	  technical	  replicates.
if	  n<	  5,	  the	  individual	  data	  points	  from	  each	  experiment	  should	  be	  plotted	  and	  any	  statistical	  test	  employed	  should	  be	  
justified
Please	  fill	  out	  these	  boxes	  	  (Do	  not	  worry	  if	  you	  cannot	  see	  all	  your	  text	  once	  you	  press	  return)
a	  specification	  of	  the	  experimental	  system	  investigated	  (eg	  cell	  line,	  species	  name).
C-­‐	  Reagents
B-­‐	  Statistics	  and	  general	  methods
the	  assay(s)	  and	  method(s)	  used	  to	  carry	  out	  the	  reported	  observations	  and	  measurements	  
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  being	  measured.
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  altered/varied/perturbed	  in	  a	  controlled	  manner.
the	  exact	  sample	  size	  (n)	  for	  each	  experimental	  group/condition,	  given	  as	  a	  number,	  not	  a	  range;
a	  description	  of	  the	  sample	  collection	  allowing	  the	  reader	  to	  understand	  whether	  the	  samples	  represent	  technical	  or	  
biological	  replicates	  (including	  how	  many	  animals,	  litters,	  cultures,	  etc.).
Each	  figure	  caption	  should	  contain	  the	  following	  information,	  for	  each	  panel	  where	  they	  are	  relevant:
2.	  Captions
The	  data	  shown	  in	  figures	  should	  satisfy	  the	  following	  conditions:
Source	  Data	  should	  be	  included	  to	  report	  the	  data	  underlying	  graphs.	  Please	  follow	  the	  guidelines	  set	  out	  in	  the	  author	  ship	  
guidelines	  on	  Data	  Presentation.
a	  statement	  of	  how	  many	  times	  the	  experiment	  shown	  was	  independently	  replicated	  in	  the	  laboratory.
Any	  descriptions	  too	  long	  for	  the	  figure	  legend	  should	  be	  included	  in	  the	  methods	  section	  and/or	  with	  the	  source	  data.
Please	  ensure	  that	  the	  answers	  to	  the	  following	  questions	  are	  reported	  in	  the	  manuscript	  itself.	  We	  encourage	  you	  to	  include	  a	  
specific	  subsection	  in	  the	  methods	  section	  for	  statistics,	  reagents,	  animal	  models	  and	  human	  subjects.	  	  
In	  the	  pink	  boxes	  below,	  provide	  the	  page	  number(s)	  of	  the	  manuscript	  draft	  or	  figure	  legend(s)	  where	  the	  
information	  can	  be	  located.	  Every	  question	  should	  be	  answered.	  If	  the	  question	  is	  not	  relevant	  to	  your	  research,	  
please	  write	  NA	  (non	  applicable).
Manuscript	  Number:	  	  EMBOJ-­‐2016-­‐94058
EMBO	  PRESS	  
A-­‐	  Figures	  
Reporting	  Checklist	  For	  Life	  Sciences	  Articles	  (Rev.	  July	  2015)
This	  checklist	  is	  used	  to	  ensure	  good	  reporting	  standards	  and	  to	  improve	  the	  reproducibility	  of	  published	  results.	  These	  guidelines	  are	  
consistent	  with	  the	  Principles	  and	  Guidelines	  for	  Reporting	  Preclinical	  Research	  issued	  by	  the	  NIH	  in	  2014.	  Please	  follow	  the	  journal’s	  
authorship	  guidelines	  in	  preparing	  your	  manuscript.	  	  
PLEASE	  NOTE	  THAT	  THIS	  CHECKLIST	  WILL	  BE	  PUBLISHED	  ALONGSIDE	  YOUR	  PAPER
Journal	  Submitted	  to:	  EMBO	  J
Corresponding	  Author	  Name:	  Wantao	  Chen
7.	  Identify	  the	  source	  of	  cell	  lines	  and	  report	  if	  they	  were	  recently	  authenticated	  (e.g.,	  by	  STR	  profiling)	  and	  tested	  for	  
mycoplasma	  contamination.
*	  for	  all	  hyperlinks,	  please	  see	  the	  table	  at	  the	  top	  right	  of	  the	  document
8.	  Report	  species,	  strain,	  gender,	  age	  of	  animals	  and	  genetic	  modification	  status	  where	  applicable.	  Please	  detail	  housing	  
and	  husbandry	  conditions	  and	  the	  source	  of	  animals.
Adult	  male	  ICR	  mice	  were	  fasted	  overnight	  prior	  to	  drug	  administration.	  GNA002	  was	  
administered	  as	  a	  single	  dose	  of	  12	  mg/kg	  by	  tail	  vain	  injection	  or	  oral	  gavage.	  At	  pre-­‐dose	  
and	  at	  0.083,	  0.25,	  0.5,	  1,	  2,	  4,	  8,	  and	  24	  hours	  post-­‐dose,	  blood	  was	  collected	  from	  three	  
male	  mice	  and	  immediately	  processed	  for	  plasma	  by	  centrifugation	  for	  10	  minutes	  at	  3,000	  
×g.	  The	  resulting	  plasma	  was	  frozen	  on	  dry	  ice,	  and	  the	  samples	  were	  stored	  at	  -­‐80°C	  until	  
analysis.	  Proper	  measures	  were	  taken	  to	  minimize	  pain	  and	  discomfort	  experienced	  by	  the	  
mice.	  The	  experimental	  procedures	  were	  in	  accordance	  with	  the	  National	  Institutes	  of	  
Health	  Guide	  for	  Care	  and	  Use	  of	  Laboratory	  Animals	  (revised	  1996).
9.	  For	  experiments	  involving	  live	  vertebrates,	  include	  a	  statement	  of	  compliance	  with	  ethical	  regulations	  and	  identify	  the	  
committee(s)	  approving	  the	  experiments.
10.	  We	  recommend	  consulting	  the	  ARRIVE	  guidelines	  (see	  link	  list	  at	  top	  right)	  (PLoS	  Biol.	  8(6),	  e1000412,	  2010)	  to	  ensure	  
that	  other	  relevant	  aspects	  of	  animal	  studies	  are	  adequately	  reported.	  See	  author	  guidelines,	  under	  ‘Reporting	  
Guidelines’.	  See	  also:	  NIH	  (see	  link	  list	  at	  top	  right)	  and	  MRC	  (see	  link	  list	  at	  top	  right)	  recommendations.	  	  Please	  confirm	  
compliance.
11.	  Identify	  the	  committee(s)	  approving	  the	  study	  protocol.
12.	  Include	  a	  statement	  confirming	  that	  informed	  consent	  was	  obtained	  from	  all	  subjects	  and	  that	  the	  experiments	  
conformed	  to	  the	  principles	  set	  out	  in	  the	  WMA	  Declaration	  of	  Helsinki	  and	  the	  Department	  of	  Health	  and	  Human	  
Services	  Belmont	  Report.
13.	  For	  publication	  of	  patient	  photos,	  include	  a	  statement	  confirming	  that	  consent	  to	  publish	  was	  obtained.
14.	  Report	  any	  restrictions	  on	  the	  availability	  (and/or	  on	  the	  use)	  of	  human	  data	  or	  samples.
15.	  Report	  the	  clinical	  trial	  registration	  number	  (at	  ClinicalTrials.gov	  or	  equivalent),	  where	  applicable.
16.	  For	  phase	  II	  and	  III	  randomized	  controlled	  trials,	  please	  refer	  to	  the	  CONSORT	  flow	  diagram	  (see	  link	  list	  at	  top	  right)	  
and	  submit	  the	  CONSORT	  checklist	  (see	  link	  list	  at	  top	  right)	  with	  your	  submission.	  See	  author	  guidelines,	  under	  
‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  submitted	  this	  list.
17.	  For	  tumor	  marker	  prognostic	  studies,	  we	  recommend	  that	  you	  follow	  the	  REMARK	  reporting	  guidelines	  (see	  link	  list	  at	  
top	  right).	  See	  author	  guidelines,	  under	  ‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  followed	  these	  guidelines.
18.	  Provide	  accession	  codes	  for	  deposited	  data.	  See	  author	  guidelines,	  under	  ‘Data	  Deposition’.
Data	  deposition	  in	  a	  public	  repository	  is	  mandatory	  for:
a.	  Protein,	  DNA	  and	  RNA	  sequences
b.	  Macromolecular	  structures
c.	  Crystallographic	  data	  for	  small	  molecules
d.	  Functional	  genomics	  data	  
e.	  Proteomics	  and	  molecular	  interactions
19.	  Deposition	  is	  strongly	  recommended	  for	  any	  datasets	  that	  are	  central	  and	  integral	  to	  the	  study;	  please	  consider	  the	  
journal’s	  data	  policy.	  If	  no	  structured	  public	  repository	  exists	  for	  a	  given	  data	  type,	  we	  encourage	  the	  provision	  of	  
datasets	  in	  the	  manuscript	  as	  a	  Supplementary	  Document	  (see	  author	  guidelines	  under	  ‘Expanded	  View’	  or	  in	  
unstructured	  repositories	  such	  as	  Dryad	  (see	  link	  list	  at	  top	  right)	  or	  Figshare	  (see	  link	  list	  at	  top	  right).
20.	  Access	  to	  human	  clinical	  and	  genomic	  datasets	  should	  be	  provided	  with	  as	  few	  restrictions	  as	  possible	  while	  
respecting	  ethical	  obligations	  to	  the	  patients	  and	  relevant	  medical	  and	  legal	  issues.	  If	  practically	  possible	  and	  compatible	  
with	  the	  individual	  consent	  agreement	  used	  in	  the	  study,	  such	  data	  should	  be	  deposited	  in	  one	  of	  the	  major	  public	  access-­‐
controlled	  repositories	  such	  as	  dbGAP	  (see	  link	  list	  at	  top	  right)	  or	  EGA	  (see	  link	  list	  at	  top	  right).
21.	  As	  far	  as	  possible,	  primary	  and	  referenced	  data	  should	  be	  formally	  cited	  in	  a	  Data	  Availability	  section.	  Please	  state	  
whether	  you	  have	  included	  this	  section.
Examples:
Primary	  Data
Wetmore	  KM,	  Deutschbauer	  AM,	  Price	  MN,	  Arkin	  AP	  (2012).	  Comparison	  of	  gene	  expression	  and	  mutant	  fitness	  in	  
Shewanella	  oneidensis	  MR-­‐1.	  Gene	  Expression	  Omnibus	  GSE39462
Referenced	  Data
Huang	  J,	  Brown	  AF,	  Lei	  M	  (2012).	  Crystal	  structure	  of	  the	  TRBD	  domain	  of	  TERT	  and	  the	  CR4/5	  of	  TR.	  Protein	  Data	  Bank	  
4O26
AP-­‐MS	  analysis	  of	  human	  histone	  deacetylase	  interactions	  in	  CEM-­‐T	  cells	  (2013).	  PRIDE	  PXD000208
22.	  Computational	  models	  that	  are	  central	  and	  integral	  to	  a	  study	  should	  be	  shared	  without	  restrictions	  and	  provided	  in	  a	  
machine-­‐readable	  form.	  	  The	  relevant	  accession	  numbers	  or	  links	  should	  be	  provided.	  When	  possible,	  standardized	  
format	  (SBML,	  CellML)	  should	  be	  used	  instead	  of	  scripts	  (e.g.	  MATLAB).	  Authors	  are	  strongly	  encouraged	  to	  follow	  the	  
MIRIAM	  guidelines	  (see	  link	  list	  at	  top	  right)	  and	  deposit	  their	  model	  in	  a	  public	  database	  such	  as	  Biomodels	  (see	  link	  list	  
at	  top	  right)	  or	  JWS	  Online	  (see	  link	  list	  at	  top	  right).	  If	  computer	  source	  code	  is	  provided	  with	  the	  paper,	  it	  should	  be	  
deposited	  in	  a	  public	  repository	  or	  included	  in	  supplementary	  information.
23.	  Could	  your	  study	  fall	  under	  dual	  use	  research	  restrictions?	  Please	  check	  biosecurity	  documents	  (see	  link	  list	  at	  top	  
right)	  and	  list	  of	  select	  agents	  and	  toxins	  (APHIS/CDC)	  (see	  link	  list	  at	  top	  right).	  According	  to	  our	  biosecurity	  guidelines,	  














The	  human	  head	  and	  neck	  cancer	  cell	  lines	  UMSCC-­‐12	  and	  SCC-­‐25	  as	  well	  as	  breast	  cancer	  cell	  
lines	  MDA-­‐MB-­‐231,	  MDA-­‐MB-­‐468,	  and	  MCF-­‐7	  and	  their	  drug-­‐resistant	  variant	  MCF-­‐7/ADM	  were	  
obtained	  from	  the	  American	  Type	  Culture	  Collection.	  The	  human	  head	  and	  neck	  cell	  lines	  HN-­‐4,	  HN-­‐
6,	  HN-­‐12,	  HN-­‐13,	  HN-­‐30,	  Cal-­‐27,	  KB,	  and	  KB/VCR;	  the	  hepatocyte	  carcinoma	  cell	  line	  SMMC-­‐7721;	  
and	  the	  cervical	  cancer	  cell	  line	  HeLa	  were	  obtained	  from	  NIH.	  These	  cells	  were	  maintained	  in	  
Dulbecco's	  minimum	  essential	  medium	  (Invitrogen)	  that	  was	  supplemented	  with	  10%	  fetal	  bovine	  
serum,	  100	  units/ml	  penicillin,	  and	  100	  μg/ml	  streptomycin.	  MV4-­‐11,	  RS4-­‐11,	  Reh,	  Daudi,	  Pfeiffer	  
and	  KE-­‐37	  were	  obtained	  from	  the	  American	  Type	  Culture	  Collection	  and	  cultured	  with	  RPMI-­‐1640	  
medium	  and	  10%	  fetal	  bovine	  serum	  (Invitrogen).	  The	  indicated	  cell	  lines	  were	  incubated	  in	  a	  
humidified	  atmosphere	  with	  5%	  CO2	  at	  37°C.
Animal	  experiments
Male	  BALB/C	  nude	  mice,	  aged	  30-­‐35	  days	  and	  weighing	  18-­‐22	  g,	  were	  used	  for	  the	  animal	  
experiments.	  The	  mice	  were	  maintained	  in	  autoclaved	  filter-­‐top	  micro-­‐isolator	  cages	  with	  
autoclaved	  water	  and	  sterile	  food	  ad	  libitum.	  The	  cages	  were	  kept	  in	  an	  isolator	  unit	  that	  was	  
provided	  with	  filtered	  air.	  To	  generate	  the	  results	  for	  Fig	  5,	  thirty	  mice	  were	  subcutaneously	  
inoculated	  with	  injections	  of	  1×106	  cells/nude	  mice.	  After	  5	  days,	  the	  tumor	  sizes	  were	  
determined	  using	  micrometer	  calipers,	  and	  the	  nude	  mice	  with	  similar	  tumor	  volumes	  (eliminating	  
mice	  with	  tumors	  that	  were	  too	  large	  or	  too	  small)	  were	  then	  randomly	  divided	  into	  3	  groups	  (10	  
nude	  mice	  per	  group):	  the	  saline	  tumor	  control	  group	  (negative	  control	  group);	  the	  oral	  gavage	  
group	  with	  the	  oral	  administration	  of	  GNA002	  100	  mg/kg/day	  group;	  and	  the	  intraperitoneal	  
injection	  (i.p.)	  group	  with	  intro	  injection	  of	  cisplatin	  5	  mg/kg/week	  group.	  At	  the	  end	  of	  4	  weeks,	  
the	  nude	  mice	  were	  sacrificed,	  and	  the	  tumor	  xenografts	  were	  excised	  and	  measured.	  Tumor	  
volume	  (TV)	  was	  calculated	  using	  the	  following	  formula:	  TV	  (mm3)=d2×D/2,	  where	  d	  and	  D	  are	  the	  
shortest	  and	  the	  longest	  diameters,	  respectively.	  The	  entire	  experimental	  procedure	  was	  
performed	  in	  accordance	  with	  the	  National	  Institutes	  of	  Health	  Guide	  for	  Care	  and	  Use	  of	  
Laboratory	  Animals	  (revised	  1996).	  In	  addition,	  the	  animals	  were	  weighed	  twice	  per	  week	  and	  
monitored	  for	  mortality	  throughout	  the	  experimental	  period	  to	  assess	  treatment	  toxicity.
Pharmacokinetic	  study
The	  experiments	  were	  performed	  in	  compliance	  with	  ethical	  regulations	  and	  the	  protocols	  were	  
approved	  by	  the	  institute’s	  committee.
We	  confirm	  compliance	  with	  the	  recommended	  ARRIVE	  guidelines.
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